Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
The next Neuren? Nyrada chases after two big markets – stroke and traumatic brain injury
News
ASX Large Caps: NextDC jumps while Flight Centre and Neuren slump; Aussie inflation at two-year low
Health & Biotech
ASX Health Stocks: Neuren’s sales come in at top of guidance range, crushing short seller’s claims
Health & Biotech
Diagnosing mental disorder through sleep: How TrivarX could capture this huge research market
Health & Biotech
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again
News
Closing Bell: Material gains for the ASX on Friday while a good week at work sees Tech Sector gain 7.5pc
News
ASX Large Caps: Lithium stocks rebound; Neuren down 15pc after being attacked by short seller
Health & Biotech
ScoPo’s Powerplays: ASX health stocks tumble as CSL bleeds after Phase III trial misses endpoint
News
ASX Large Caps: ASX claims record high as IGO shuts down nickel project; CPI cools down more than expected
Health & Biotech
The next Neuren? These ASX biotech stocks have pending FDA catalysts in 2024
Health & Biotech
ASX Health Winners December: Health stocks beat market, look ‘undervalued’ going into 2024
Health & Biotech
Check Up: The reason people quit weight-loss drugs
Health & Biotech
Part 1: ASX biotechs with catalysts looking to pop in 2024
Health & Biotech
ScoPo’s Powerplays: ASX healthcare rises in Christmas rally as EBOS ups stake in Transmedic
Health & Biotech
ScoPo gives his NINE picks to fill the Christmas stocking with some ASX health stocks
News
Closing Bell: Relaxed ASX successfully humps Wednesday
News